Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458506071333v1
13/5/683    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alanoglu, G.
Right arrow Articles by Kutluhan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alanoglu, G.
Right arrow Articles by Kutluhan, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on June 1, 2007
Multiple Sclerosis, Vol. 13, No. 5, 683-685 (2007)
DOI: 10.1177/1352458506071333

Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis

G. Alanoglu

Department of Internal Medicine, Division of Hematology, School of Medicine, Suleyman Demirel University, 32100 Isparta, Turkey, guchan{at}med.sdu.edu.tr

S. Kilbas

Department of Neurology, School of Medicine, Suleyman Demirel University, Isparta, Turkey

C. Arslan

Department of Internal Medicine, School of Medicine, Suleyman Demirel University, Isparta, Turkey

A. Senol

Department of Internal Medicine, School of Medicine, Suleyman Demirel University, Isparta, Turkey

S. Kutluhan

Department of Neurology, School of Medicine, Suleyman Demirel University, Isparta, Turkey

A 31-year-old patient with multiple sclerosis (MS), treated with interferon beta-1b (IFNB-1b) for two years, presented with fatigue and dizziness. Coombs' positive autoimmune hemolytic anemia (AIHA) was found. Other potential etiologies of AIHA were ruled out. An association with IFNB-1b was highly suspected. Interferon therapy was discontinued and prednisone therapy instituted. There was resolution of the hemolytic anemia, and prednisone therapy was tapered gradually. To the best of our knowledge, there is no reported case of the development of AIHA associated with IFNB-1b use in MS patients. We conclude that if an unexplained drop in hematocrit occurs with a MS patient receiving IFNB-1b, autoimmune mediated hemolysis should also be considered. Multiple Sclerosis 2007; 13: 683-685. http://msj.sagepub.com

Key Words: autoimmune hemolytic anemia • interferon beta-1b treatment • multiple sclerosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
M. Krumbholz, H. Faber, F. Steinmeyer, L.-A. Hoffmann, T. Kumpfel, H. Pellkofer, T. Derfuss, C. Ionescu, M. Starck, C. Hafner, et al.
Interferon-{beta} increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity
Brain, June 1, 2008; 131(6): 1455 - 1463.
[Abstract] [Full Text] [PDF]